Tempest TherapeuticsTPST
About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Employees: 25
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
44% more capital invested
Capital invested by funds: $3.94M [Q3] → $5.67M (+$1.73M) [Q4]
25% more funds holding
Funds holding: 28 [Q3] → 35 (+7) [Q4]
4.31% more ownership
Funds ownership: 11.23% [Q3] → 15.54% (+4.31%) [Q4]
66% less call options, than puts
Call options by funds: $45K | Put options by funds: $131K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Scotiabank George Farmer 24% 1-year accuracy 5 / 21 met price target | 17%upside $9 | Sector Perform Downgraded | 10 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 82 / 415 met price target | 108%upside $16 | Neutral Downgraded | 10 Apr 2025 |
Financial journalist opinion
Based on 4 articles about TPST published over the past 30 days









